Long-term kidney graft survival by delayed T cell ablative treatment in rhesus monkeys

Transplantation
M JonkerR Calne

Abstract

Tolerance to organ allografts in primates including man has been elusive, although in rodents and pigs tolerance can be achieved to organ allografts with relatively short courses of immunosuppressive treatment. In all varieties of graft acceptance that do not require full-dose maintenance immunosuppression, immunological engagement of donor and recipient and an early unstable period have been observed. On the basis of the hypothesis that elimination of aggressive T cell function should tip the balance in favor of an operationally tolerant state, experiments have been performed in monkeys allowing recipient-donor interaction before T-cell ablation and a short course of immunosuppression. Rhesus monkeys received an allogeneic kidney graft from a MHC-mismatched donor. The animals either received anti-CD3 immunotoxin (FN18-CRM9) alone, started 2 days after transplantation, or in combination with a short course of cyclosporine (CsA) and/or rapamycin (RAPA), started at 5 days after transplantation. Kidney function was followed by monitoring serum creatinine levels and regular biopsies. Humoral and cellular antidonor immunity was tested in vitro before and at several time points after transplantation. Graft survival of monkeys that re...Continue Reading

References

Jun 27, 1992·Lancet·T E StarzlM Trucco
Mar 1, 1996·Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy·D M NevilleM Jonker
Jan 15, 1997·Transplantation·S J KnechtleD M Neville
Feb 13, 1999·Kidney International·L C RacusenY Yamaguchi
Mar 8, 2000·The Journal of Immunology : Official Journal of the American Association of Immunologists·G G DoxiadisR E Bontrop
Mar 24, 2000·Clinical Immunology : the Official Journal of the Clinical Immunology Society·D H Sachs
Jun 1, 2000·World Journal of Surgery·R Y Calne
Aug 30, 2000·Lancet·P F Halloran

❮ Previous
Next ❯

Citations

Mar 18, 2003·Transplantation·Krista G HaanstraMargreet Jonker
Apr 24, 2008·Transplantation·Krista G HaanstraMargreet Jonker
Dec 29, 2015·Current Opinion in Organ Transplantation·William H Kitchens, Andrew B Adams
Sep 12, 2007·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·K G HaanstraM Jonker
Sep 24, 2004·Transplant Immunology·Thomas Fehr, Megan Sykes
Jul 24, 2003·Nature Reviews. Immunology·Juraj Ivanyi
Apr 22, 2004·The Journal of Immunology : Official Journal of the American Association of Immunologists·Jose R TorrealbaStuart J Knechtle

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.